Publications by authors named "Martin Swarbrick"

Claim this Profile
C
Correction to "Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta".
Martin L Stockley, Giovanni Benedetti, Peter Blencowe, Simon J Boulton, Susan M Boyd, Martin E Swarbrick

J Med Chem· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta.
Martin L Stockley, Amanda Ferdinand, Giovanni Benedetti, Peter Blencowe, Susan M Boyd, Martin E Swarbrick

J Med Chem· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and optimization of a novel series of selective PIP5K inhibitors.
David M Andrews, Sharon Cartic, Sabina Cosulich, Nullin Divecha, Paul Faulder, Martin E Swarbrick

Bioorg Med Chem· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Diana Zatreanu, Helen M R Robinson, Omar Alkhatib, Marie Boursier, Harry Finch, Martin Swarbrick

Nat Commun· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MNK Inhibition Sensitizes -Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression.
John R P Knight, Constantinos Alexandrou, George L Skalka, Nikola Vlahov, Kathryn Pennel, Martin E Swarbrick

Cancer Discov· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP receptor partial agonist for the treatment of pain.
Mark P Healy, Amanda C Allan, Kristin Bailey, Andy Billinton, Iain P Chessell, Martin E Swarbrick

Bioorg Med Chem Lett· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent, selective small molecule inhibitors of α-subtype of type III phosphatidylinositol-4-kinase (PI4KIIIα).
Piotr Raubo, David M Andrews, Jennifer C McKelvie, Graeme R Robb, James M Smith, Martin E Swarbrick

Bioorg Med Chem Lett· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation.
Michael J Waring, David M Andrews, Paul F Faulder, Vikki Flemington, Jennifer C McKelvie, Martin E Swarbrick

Chem Commun (Camb)· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface.
David M Andrews, Martin E Swarbrick, Andrew T Merritt

Drug Discov Today· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-based hit identification: thinking in 3D.
Andrew D Morley, Angelo Pugliese, Kristian Birchall, Justin Bower, Paul Brennan, Martin E Swarbrick

Drug Discov Today· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB(2) agonists for the treatment of inflammatory pain.
Robert J Gleave, Paul J Beswick, Andrew J Brown, Gerard M P Giblin, Paul Goldsmith, Martin E Swarbrick

Bioorg Med Chem Lett· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Amino-5-aryl-pyridines as selective CB2 agonists: synthesis and investigation of structure-activity relationships.
Robert J Gleave, Paul J Beswick, Andrew J Brown, Gerard M P Giblin, Carl P Haslam, Martin E Swarbrick

Bioorg Med Chem Lett· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
Martin E Swarbrick, Paul J Beswick, Robert J Gleave, Richard H Green, Sharon Bingham

Bioorg Med Chem Lett· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enantioselective Baeyer-Villiger oxidation catalyzed by palladium(II) complexes with chiral P,N-ligands.
Andrei V Malkov, Frédéric Friscourt, Mark Bell, Martin E Swarbrick, Pavel Kocovský

J Org Chem· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alkyl Substituent Effects on Pipecolyl Amide Isomer Equilibrium: Efficient Methodology for Synthesizing Enantiopure 6-Alkylpipecolic Acids and Conformational Analysis of Their N-Acetyl N'-Methylamides.
Martin E. Swarbrick, Francis Gosselin, William D. Lubell

J Org Chem· March 1999

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Silicon-Assisted Aza-[2,3]-Wittig Sigmatropic Rearrangement.
James C. Anderson, D. Craig Siddons, Stephen C. Smith, Martin E. Swarbrick

J Org Chem· July 1996

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis